Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 10 mechanisms across 31 industry trials with a known mechanism of action.

See full pipeline →

Alkylating Drug

10 trials 2 active 9 sponsors

Vascular Endothelial Growth Factor Inhibitor

7 trials 2 active 5 sponsors

Platinum-based Drug

4 trials 1 active 2 sponsors

Contrast Agent for Ultrasound Imaging

1 trials 1 active 1 sponsor

Hypoxia-inducible Factor Inhibitor

1 trials 1 active 1 sponsor

Programmed Death Receptor-1 Blocking Antibody

3 trials 3 sponsors

Nuclear Export Inhibitor

2 trials 1 sponsor

Kinase Inhibitor

1 trials 1 sponsor

ABL kinase/BCR-ABL/EPHA2/FYN/LCK/PDGFRβ/SRC/YES/c-KIT

1 trials 1 sponsor

DNA

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

284 industry-sponsored trials across 180 sponsors

View full landscape →

Showing 5 of 5 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novartis	dabrafenib	—	RECRUITING	2026-11-05	NCT03975829
GT Medical Technologies, Inc.	—	—	ACTIVE NOT RECRUITING	2027-12-01	NCT05342883
Merck	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2011-09-28	NCT00686725
NovoCure Ltd.	—	—	TERMINATED	2018-01	NCT01756729
GT Medical Technologies, Inc.	—	—	WITHDRAWN	2026-06	NCT05900908

Showing 30 of 30 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
NaviFUS Corporation	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	RECRUITING	2026-12-31	NCT06496971
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	RECRUITING	2027-07	NCT07100730
CarThera	Carboplatin	Platinum-based Drug [EPC]	RECRUITING	2028-01-28	NCT05902169
NovoCure GmbH	Temozolomide	Alkylating Drug [EPC]	RECRUITING	2029-04	NCT06556563
GT Medical Technologies, Inc.	Temozolomide	Alkylating Drug [EPC]	RECRUITING	2031-12	NCT07195591
TVAX Biomedical	TVI-Brain-1	—	ACTIVE NOT RECRUITING	2026-12	NCT05685004
Laminar Pharmaceuticals	LAM561	—	ACTIVE NOT RECRUITING	2026-01-15	NCT04250922
Ascletis Pharmaceuticals Co., Ltd.	ASC40 tablets	—	ACTIVE NOT RECRUITING	2025-06	NCT05118776
Beijing Pearl Biotechnology Limited Liability Company	PLB1001	—	ACTIVE NOT RECRUITING	2023-04-01	NCT06105619
Aivita Biomedical, Inc.	AV-GBM-1	—	NOT YET RECRUITING	2028-03	NCT05100641
Everfront Biotech Co., Ltd.	Cerebraca wafer	—	NOT YET RECRUITING	2028-12-01	NCT07349693
Denovo Biopharma LLC	Enzastaurin Hydrochloride	—	COMPLETED	2024-02-29	NCT03776071
Cordgenics, LLC	Chemotherapy	—	COMPLETED	2022-06-16	NCT03632135
AbbVie	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2022-04-04	NCT02573324
Sumitomo Pharma America, Inc.	DSP-7888 Dosing Emulsion	—	COMPLETED	2021-08-30	NCT03149003
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-06-17	NCT02017717
Vascular Biogenics Ltd. operating as VBL Therapeutics	VB-111 + bevacizumab	—	COMPLETED	2017-11-03	NCT02511405
NovoCure Ltd.	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2016-12	NCT00916409
Celldex Therapeutics	Rindopepimut (CDX-110) with GM-CSF	—	COMPLETED	2016-11	NCT01480479
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2013-02-28	NCT00943826
EMD Serono	Cilengitide	—	COMPLETED	2012-11	NCT00689221
GC Cell Corporation	Activated T lymphocyte(Immuncell-LC)	—	COMPLETED	2012-10	NCT00807027
AstraZeneca	Cediranib	—	COMPLETED	2010-04	NCT00777153
Diffusion Pharmaceuticals Inc	Trans Sodium Crocetinate plus SOC	—	TERMINATED	2020-11-06	NCT03393000
AbbVie	Steroid eye drops	—	TERMINATED	2019-09-05	NCT03419403
DelMar Pharmaceuticals, Inc.	VAL-083, Dianhydrogalactitol	—	TERMINATED	2019-05-31	NCT03149575
Tocagen Inc.	Toca 511	—	TERMINATED	2019-05-31	NCT02414165
Bradmer Pharmaceuticals Inc.	Neuradiab + Radiotherapy + Temozolomide	—	TERMINATED	2013-08	NCT00615186
Isarna Therapeutics GmbH	trabedersen	—	TERMINATED	2012-02	NCT00761280
Precision Life Sciences Group	ICT-107	—	SUSPENDED	2025-12	NCT02546102

Showing 100 of 151 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
JenKem Technology Co., Ltd.	JK-1201I	—	RECRUITING	2026-08-16	NCT06595186
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1 for Injection	—	RECRUITING	2026-10	NCT06598787
Philogen S.p.A.	Onfekafusp alfa	—	RECRUITING	2026-10	NCT04443010
Myosin Therapeutics Inc.	MT-125	—	RECRUITING	2026-10-31	NCT07185880
Ever Supreme Bio Technology Co., Ltd.	autologous dendritic cells	—	RECRUITING	2026-12-30	NCT04115761
Neonc Technologies, Inc.	NEO212 Oral Capsule	—	RECRUITING	2027-02-28	NCT06047379
Tango Therapeutics, Inc.	TNG456	—	RECRUITING	2027-03-31	NCT06810544
Filamon LTD	A novel hGIIA-Vimentin Inhibitor	—	RECRUITING	2027-10-26	NCT06926075
Alpheus Medical, Inc.	—	—	RECRUITING	2027-12	NCT07225621
NaviFUS Corporation	Lumason	Contrast Agent for Ultrasound Imaging [EPC]	RECRUITING	2027-12-31	NCT06329570
BioNTech SE	Pumitamig	—	RECRUITING	2028-01	NCT07297212
Tasly Pharmaceutical Group Co., Ltd	P134 cell injection	—	RECRUITING	2028-02-29	NCT07318818
Debiopharm International SA	Debio 0123	—	RECRUITING	2028-09	NCT05765812
Black Diamond Therapeutics, Inc.	silevertinib in combination with temozolomide	—	RECRUITING	2028-11	NCT07326566
Guangzhou Virotech Pharmaceutical Co., Ltd.	VRT106	—	RECRUITING	2028-12-31	NCT07093814
ImmunityBio, Inc.	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	RECRUITING	2029-12-31	NCT06061809
Trogenix ltd	TGX-007	—	RECRUITING	2030-03	NCT07346144
Diakonos Oncology Corporation	DOC1021	—	RECRUITING	2030-03	NCT06805305
Jecho Biopharmaceuticals Co., Ltd.	JL15003Injection	—	RECRUITING	2030-04	NCT07501559
Neonc Technologies, Inc.	Perillyl alcohol	—	RECRUITING	2026-03-30	NCT02704858
Apollomics Inc.	APL-101 Oral Capsules	—	RECRUITING	2026-03-30	NCT03175224
SignPath Pharma, Inc.	Treatment Period 1	—	RECRUITING	2026-02	NCT05768919
Aveta Biomics, Inc.	APG-157	—	RECRUITING	2025-12-31	NCT06011109
Hemerion Therapeutics	—	—	RECRUITING	2025-12	NCT05736406
Marzieh Ebrahimi	NK cell therapy	—	RECRUITING	2025-11-25	NCT06687681
Philogen S.p.A.	L19TNF	—	ACTIVE NOT RECRUITING	2026-06	NCT06336291
Imvax	SOC: Temozolomide	—	ACTIVE NOT RECRUITING	2026-06	NCT04485949
Genenta Science	Temferon	—	ACTIVE NOT RECRUITING	2026-06-30	NCT03866109
NuvOx LLC	NanO2TM	—	ACTIVE NOT RECRUITING	2026-06-30	NCT03862430
Lantern Pharma Inc.	LP-184	—	ACTIVE NOT RECRUITING	2026-07-28	NCT05933265
BPGbio	BPM31510	—	ACTIVE NOT RECRUITING	2026-08-25	NCT04752813
Cantex Pharmaceuticals	Azeliragon	—	ACTIVE NOT RECRUITING	2026-09-30	NCT05986851
GSK	Cobolimab	—	ACTIVE NOT RECRUITING	2026-10-13	NCT06521567
Sapience Therapeutics	ST101	—	ACTIVE NOT RECRUITING	2026-12	NCT04478279
Cantex Pharmaceuticals	Azeliragon 5 mg	—	ACTIVE NOT RECRUITING	2026-12	NCT05635734
Inovio Pharmaceuticals	INO-5401	—	ACTIVE NOT RECRUITING	2026-12-31	NCT03491683
Polaris Group	ADI-PEG 20	—	ACTIVE NOT RECRUITING	2027-02-28	NCT04587830
Nerviano Medical Sciences	NMS-03305293	—	ACTIVE NOT RECRUITING	2027-05-30	NCT04910022
TME Pharma AG	Olaptesed pegol	—	ACTIVE NOT RECRUITING	2028-12	NCT04121455
CNS Pharmaceuticals, Inc.	Berubicin	—	ACTIVE NOT RECRUITING	2026-04-27	NCT04762069
photonamic GmbH & Co. KG	5-aminolevulinic acid	—	ACTIVE NOT RECRUITING	2026-03	NCT03897491
Epitopoietic Research Corporation	ERC1671	—	ACTIVE NOT RECRUITING	2026-03	NCT01903330
In8bio Inc.	Autologous genetically modified gamma-delta T cells	—	ACTIVE NOT RECRUITING	2025-12	NCT05664243
NGM Biopharmaceuticals, Inc	NGM707	—	ACTIVE NOT RECRUITING	2025-02	NCT04913337
Acerta Pharma BV	ACP-196	—	ACTIVE NOT RECRUITING	2020-06-26	NCT02586857
Starlight Therapeutics Inc.	STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.	—	NOT YET RECRUITING	2027-05-01	NCT07431216
Sichuan Honghe Biotechnology Co., Ltd.	KH617	—	NOT YET RECRUITING	2027-09	NCT07138001
T-MAXIMUM Pharmaceutical Inc	Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3	—	NOT YET RECRUITING	2028-12-13	NCT07386002
ZSky Biotech Inc	Personalized Dendritic Cell Vaccine ZSNeo-DC1.1	—	NOT YET RECRUITING	2028-12-24	NCT07365280
CRISM Therapeutics LTD	irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM	—	NOT YET RECRUITING	2029-05	NCT07356973
NeuGATE Theranostics	Temozolomide	Alkylating Drug [EPC]	NOT YET RECRUITING	2030-07-30	NCT04373785
PharmaMar	Lurbinectedin	Alkylating Drug [EPC]	COMPLETED	2025-07-01	NCT02611024
Kintara Therapeutics, Inc.	VAL-083, Dianhydrogalactitol	—	COMPLETED	2024-12-30	NCT02717962
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2024-10-28	NCT03797326
Istari Oncology, Inc.	lerapolturev	—	COMPLETED	2024-06-05	NCT04479241
Oblato, Inc.	OKN-007	—	COMPLETED	2024-05-08	NCT04388475
Enterome	Multiple dose of EO2401	—	COMPLETED	2024-03-04	NCT04116658
InSightec	Carboplatin	Platinum-based Drug [EPC]	COMPLETED	2023-11-30	NCT04417088
InSightec	Carboplatin	Platinum-based Drug [EPC]	COMPLETED	2023-11-30	NCT04440358
BioMimetix JV, LLC	BMX-001	—	COMPLETED	2023-08-17	NCT02655601
MediciNova	MN-166	—	COMPLETED	2023-08-07	NCT03782415
NovoCure GmbH	—	—	COMPLETED	2023-06-20	NCT04492163
Kazia Therapeutics Limited	Paxalisib (GDC-0084)	—	COMPLETED	2023-03-30	NCT03522298
Aadi Bioscience, Inc.	nab-sirolimus	—	COMPLETED	2022-08-26	NCT03463265
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	COMPLETED	2022-07-31	NCT03849105
Gan and Lee Pharmaceuticals, USA	GLR2007	—	COMPLETED	2022-07-29	NCT04444427
Kintara Therapeutics, Inc.	VAL-083 (Dianhydrogalactitol)	—	COMPLETED	2021-11-22	NCT03050736
Novartis	Dabrafenib	—	COMPLETED	2021-08-23	NCT02684058
CarThera	Carboplatin	Platinum-based Drug [EPC]	COMPLETED	2021-06-23	NCT03744026
Bristol-Myers Squibb	MRZ	—	COMPLETED	2021-06-02	NCT02330562
Forma Therapeutics, Inc.	FT-2102	—	COMPLETED	2021-05-24	NCT03684811
DNAtrix, Inc.	DNX-2401	—	COMPLETED	2021-03-17	NCT02798406
AbbVie	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2020-08-27	NCT02590263
Arog Pharmaceuticals, Inc.	crenolanib	—	COMPLETED	2020-07	NCT02626364
Incyte Corporation	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2020-06-16	NCT02327078
Kadmon Corporation, LLC	Tesevatinib	—	COMPLETED	2020-04-30	NCT02844439
Sumitomo Pharma Co., Ltd.	DSP-7888	—	COMPLETED	2020-01	NCT02750891
CytoVac A/S	ALECSAT	—	COMPLETED	2019-11-14	NCT02799238
Medicenna Therapeutics, Inc.	MDNA55	—	COMPLETED	2019-09-12	NCT02858895
AbbVie	Depatuxizumab mafodotin	—	COMPLETED	2019-06-24	NCT02343406
Gilead	Sacituzumab Govitecan-hziy (SG)	—	COMPLETED	2019-03-01	NCT01631552
Celldex Therapeutics	Combination of varlilumab and nivolumab	—	COMPLETED	2018-12-12	NCT02335918
Sumitomo Pharma America, Inc.	BBI608	—	COMPLETED	2018-10-09	NCT02315534
Novartis	BGJ398	—	COMPLETED	2018-10-03	NCT01975701
Cantex Pharmaceuticals	Disulfiram/Copper	—	COMPLETED	2018-07-10	NCT03034135
NewLink Genetics Corporation	Indoximod	—	COMPLETED	2018-04-18	NCT02052648
Daiichi Sankyo	PLX3397	—	COMPLETED	2017-11-03	NCT01790503
Stemline Therapeutics, Inc.	SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)	—	COMPLETED	2017-09-01	NCT02078648
PharmAbcine	TTAC-0001	—	COMPLETED	2017-06-02	NCT03033524
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2017-01-13	NCT01860638
ImmunityBio, Inc.	250 mg/m2 aldoxorubicin	—	COMPLETED	2016-12	NCT02014844
GenSpera, Inc.	G-202	—	COMPLETED	2016-12	NCT02067156
Bristol-Myers Squibb	CC-223	—	COMPLETED	2016-11-15	NCT01177397
Angiochem Inc	ANG1005	—	COMPLETED	2016-02	NCT01967810
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2016-01-21	NCT01632228
Kintara Therapeutics, Inc.	VAL-083 (Dianhydrogalactitol)	—	COMPLETED	2015-12	NCT01478178
Diffusion Pharmaceuticals Inc	Trans Sodium Crocetinate (TSC)	—	COMPLETED	2015-11	NCT01465347
Vascular Biogenics Ltd. operating as VBL Therapeutics	VB-111	—	COMPLETED	2015-07-23	NCT01260506
Sanofi	bsi-201 plus temozolomide	—	COMPLETED	2015-06	NCT00687765
Tracon Pharmaceuticals Inc.	TRC105	—	COMPLETED	2015-06	NCT01564914

Showing 98 of 98 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Telix Pharmaceuticals (Innovations) Pty Limited	131I-IPA	—	RECRUITING	2026-06	NCT05450744
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.	BC008-1A	—	RECRUITING	2026-06	NCT06773481
Orbus Therapeutics, Inc.	Eflornithine (Dose Level 1)	—	RECRUITING	2026-06-30	NCT05879367
Jazz Pharmaceuticals	ONC206	—	RECRUITING	2026-07	NCT04541082
Boston Scientific Corporation	—	—	RECRUITING	2026-07-31	NCT05303467
AstraZeneca	AZD1390	—	RECRUITING	2026-09-16	NCT03423628
BeyondBio Inc.	BEY1107	—	RECRUITING	2026-11-30	NCT05769660
RasCal Therapeutics, Inc.	RSC-1255 Dose Escalation	—	RECRUITING	2026-12-15	NCT04678648
Orano Med LLC	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Beijing Biotech	Dual-target CAR-NK cells	—	RECRUITING	2027-02-18	NCT07480941
Beijing Biotech	Dual-target CAR-NK cells	—	RECRUITING	2027-04-14	NCT07551336
Tetragon Biosciences Ltd	GLIX1	—	RECRUITING	2027-06	NCT07464925
Chipscreen Biosciences, Ltd.	CS231295	—	RECRUITING	2029-04	NCT06902350
Photolitec LLC	—	—	RECRUITING	2025-05	NCT05363826
Phost'In Therapeutics	PhOx430	—	RECRUITING	2024-11-04	NCT05495295
Chimeric Therapeutics	CHM-1101 CAR-T cells	—	ACTIVE NOT RECRUITING	2026-12	NCT05627323
Novartis	[177Lu]Lu-NeoB	—	ACTIVE NOT RECRUITING	2028-11-08	NCT05739942
Immunomic Therapeutics, Inc.	ITI-1001	—	ACTIVE NOT RECRUITING	2026-03	NCT05698199
Novartis	[177Lu]Lu-DOTA-TATE	—	ACTIVE NOT RECRUITING	2025-12-03	NCT05109728
Katmai Pharmaceuticals Inc.	ERAS-801	—	ACTIVE NOT RECRUITING	2025-08-31	NCT05222802
Oblato, Inc.	Low-dose OKN-007, BID	—	ACTIVE NOT RECRUITING	2025-05-31	NCT05561374
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2018-01-12	NCT02974738
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	FZ-AD005	—	NOT YET RECRUITING	2027-12-01	NCT07455045
Crimson Biopharm Inc.	CM93	—	NOT YET RECRUITING	2029-07	NCT04933422
Beijing Tricision Biotherapeutics Inc	Survivin-loaded dendritic cell injection	—	NOT YET RECRUITING	2025-12-01	NCT06524063
Theragnostics Ltd	123I-ATT001	—	COMPLETED	2026-03-01	NCT06650605
CureVac	CV09050101 mRNA vaccine (CVGBM) 12 μg	—	COMPLETED	2026-02-02	NCT05938387
Boehringer Ingelheim	BI 907828 (Brigimadlin)	—	COMPLETED	2025-07-31	NCT05376800
Roche	RO7428731	—	COMPLETED	2025-05-14	NCT05187624
Prelude Therapeutics	PRT3645	—	COMPLETED	2024-06-26	NCT05538572
Jecho Biopharmaceuticals Co., Ltd.	JL15003 Injection	—	COMPLETED	2024-05-23	NCT07497373
Bristol-Myers Squibb	CC-122	—	COMPLETED	2023-11-21	NCT01421524
BerGenBio ASA	Bemcentinib	—	COMPLETED	2022-09-23	NCT06469138
Istari Oncology, Inc.	Polio/Rhinovirus Recombinant (PVSRIPO)	—	COMPLETED	2022-03-23	NCT03043391
Engeneic Pty Limited	EGFR(V)-EDV-Dox	—	COMPLETED	2021-08-21	NCT02766699
Bristol-Myers Squibb	CC-115	—	COMPLETED	2021-03-12	NCT01353625
Bristol-Myers Squibb	MRZ	—	COMPLETED	2021-01-25	NCT02903069
Stemgen	hrBMP4	—	COMPLETED	2020-10-16	NCT02869243
Alaunos Therapeutics	Ad-RTS-hIL-12	—	COMPLETED	2020-10-15	NCT03636477
Genexine, Inc.	GX-I7	—	COMPLETED	2020-09-25	NCT03619239
Laminar Pharmaceuticals	LAM561	—	COMPLETED	2020-07-01	NCT03867123
NewLink Genetics Corporation	Indoximod	—	COMPLETED	2019-12-12	NCT02502708
EpicentRx, Inc.	RRx-001 dose escalation with TMZ + RT	—	COMPLETED	2019-10-11	NCT02871843
Alaunos Therapeutics	Ad-RTS-hIL-12	—	COMPLETED	2019-08	NCT02026271
Incuron	CBL0137	—	COMPLETED	2019-05	NCT01905228
Alaunos Therapeutics	Ad-RTS-hIL-12	—	COMPLETED	2019-04-02	NCT03679754
CANbridge Life Sciences Ltd.	CAN008	—	COMPLETED	2018-09	NCT02853565
Sumitomo Pharma America, Inc.	DSP-7888 Dosing Emulsion	—	COMPLETED	2018-08	NCT02498665
Bristol-Myers Squibb	CC-486	—	COMPLETED	2018-06-11	NCT02223052
Immatics Biotechnologies GmbH	APVAC1 vaccine plus Poly-ICLC and GM-CSF	—	COMPLETED	2018-06	NCT02149225
DNAtrix, Inc.	Single intratumoral injection of DNX-2401	—	COMPLETED	2018-03-15	NCT02197169
Cavion, Inc.	Mibefradil with Radiation	—	COMPLETED	2017-09-29	NCT02202993
Boehringer Ingelheim	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2017-09-12	NCT00977431
NuvOx LLC	NVX-108	—	COMPLETED	2017-08-31	NCT02189109
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd	Chlorogenic acid	—	COMPLETED	2017-08-23	NCT02728349
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Bevacizumab injection	—	COMPLETED	2017-08-18	NCT05476341
Vaximm GmbH	VXM01	—	COMPLETED	2017-08	NCT02718443
Istari Oncology, Inc.	Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)	—	COMPLETED	2017-06-27	NCT01491893
AbbVie	ABT-414	—	COMPLETED	2017-06-19	NCT01800695
Novartis	BKM120 + temozolomide	—	COMPLETED	2017-05-17	NCT01473901
Kartos Therapeutics, Inc.	AMG 232	—	COMPLETED	2017-03-15	NCT01723020
Precision Life Sciences Group	ICT-121 DC vaccine	—	COMPLETED	2017-03	NCT02049489
Tocagen Inc.	Toca 511 vector	—	COMPLETED	2016-08-18	NCT01156584
Novartis	buparlisib	—	COMPLETED	2016-07-07	NCT01934361
Tocagen Inc.	Toca 511 vector	—	COMPLETED	2016-04-12	NCT01470794
Amgen	AMG 595	—	COMPLETED	2016-04	NCT01475006
Tocagen Inc.	Toca 511	—	COMPLETED	2016-03-03	NCT01985256
Novartis	LDE225	—	COMPLETED	2015-04	NCT01576666
Roche	GDC-0084	—	COMPLETED	2015-01	NCT01547546
Roche	RO5323441 + bevacizumab [Avastin]	—	COMPLETED	2013-02	NCT01308684
CytoVac A/S	ALECSAT cell based immunotherapy	—	COMPLETED	2012-11	NCT01588769
Exelixis	XL184	—	COMPLETED	2012-11	NCT00960492
Sanofi	XL765 (SAR245409)	—	COMPLETED	2012-06	NCT01240460
Merck	MK-4827	—	COMPLETED	2012-04	NCT01294735
Sanofi	XL765 (SAR245409)	—	COMPLETED	2012-02	NCT00704080
Monteris Medical	—	—	COMPLETED	2009-10	NCT00747253
Taiho Oncology, Inc.	TAS2940	—	TERMINATED	2025-02-26	NCT04982926
Novartis	68Ga-FF58	—	TERMINATED	2024-12-13	NCT05977322
Biodexa Pharmaceuticals	MTX110	—	TERMINATED	2024-09-10	NCT05324501
Bristol-Myers Squibb	CC-90010	—	TERMINATED	2024-07-09	NCT04324840
Bristol-Myers Squibb	CC-90010	—	TERMINATED	2024-06-03	NCT04047303
OncoSynergy, Inc.	OS2966	—	TERMINATED	2023-02-27	NCT04608812
Samus Therapeutics, Inc.	Icapamespib	—	TERMINATED	2022-11-04	NCT04782609
Nuvation Bio Inc.	NUV-422	—	TERMINATED	2022-08-31	NCT04541225
Basilea Pharmaceutica	Microtubule-Targeted Agent BAL101553	—	TERMINATED	2022-06-03	NCT03250299
Vanquish Oncology, Inc.	PAC-1 Compound	—	TERMINATED	2021-12-31	NCT03332355
Celularity Incorporated	CYNK001-IV	—	TERMINATED	2021-08-10	NCT04489420
Amgen	AMG 596	—	TERMINATED	2021-07-01	NCT03296696
Tocagen Inc.	Toca 511 vector	—	TERMINATED	2019-12	NCT04327011
Monteris Medical	Radiation therapy and temozolomide	—	TERMINATED	2018-09-14	NCT02880410
AbbVie	ABBV-221	—	TERMINATED	2018-03-15	NCT02365662
Actelion	Macitentan in combination with RT and TMZ	—	TERMINATED	2016-09-29	NCT02254954
Actelion	Phase 1 Dose Escalation	—	TERMINATED	2016-01	NCT01499251
Immatics Biotechnologies GmbH	Cyclophosphamide	DNA	TERMINATED	2014-04	NCT01403285
Shanghai Simnova Biotechnology Co.,Ltd.	SNC109	—	ENROLLING BY INVITATION	2024-12-31	NCT06616727
Philogen S.p.A.	Onfekafusp alfa	—	WITHDRAWN	2024-12-31	NCT05304663
Pfizer	Crizotinib plus VEGF inhibitor combinations	—	WITHDRAWN	2013-11	NCT01441388
Millennium Pharmaceuticals, Inc.	Tandutinib, bevacizumab, and temozolomide	—	WITHDRAWN	2010-05	NCT00904852

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Glioblastoma

VEGF (17)

Novel Drugs by Company (New molecular entities)

CELLTRION 1 drug

VEGZELMA

BEVACIZUMAB-ADCD

BLA 2022

Reformulations (8 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

BIO-THERA SOLUTIONS LTD